Personalized Medicine Market Raises US$ 1.7 Trillion By 2026

The Global Personalized Medicine Market Size is Projected to Reach USD 1.7 Trillion by 2026 and is expected to witness 9.1% CAGR during the forecast period 2019 to 2026.

A customized market in drugs is anticipated to grow rapidly as the incidence of diseases has increased and the focus is placed on developing medicinal products for cancer patients, which have shown greater efficacy than others. Fast findings and personalized impacts, less likelihood of drug defects as well as negative medical responses are some of the other variables that could lead to an appropriate traction in both research and development and income potential for such drugs. Governments favorable policies on personalized medicine also offer additional opportunities to take advantage of that industry. Recent developments in pharmacogenomics are anticipated to produce an appropriate medicine-specific atmosphere for one patient or group. Developing genetic databases could give the market a further boost. Therapeutic possibilities for use in areas such as neurological, antiviral, cardiovascular, pulmonary, etc. could lead to research and development traction across all areas. Some of the limitations which could impair the growth in income of the market for customized medicines for the coming years include complex drug characteristics, elevated development expenses, an inoptimal development structure, and interpatient variability of impacts.

Personalized medicines are designed to adapt treatments to a particular patient, such as diagnosis, disease, history of patients, physics and other patient / disease variables. Custom medicine is also known as medicine for accuracy, laminated medicine, or P4. Diagnostic assessment for the selection of appropriate best medicines based on the genetic material or other molecular or cellular analyzes is often done in personalized medicine. Personalized medication has the greatest reaction and margin for security to guarantee improved patient care through the early diagnosis, risk evaluation, and optimum treatment of patients. In addition, custom medicine provides possibilities to enhance healthcare by reducing the total cost of therapy.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1466

The worldwide market for personalized medicine is driven by the increased incidence of multiple cancers, the affordability of personalized treatment in carcinoma and multiple other disease signs, less side effects of personalized medicine treatment, strong acceptance in developed markets and the creation of innovative medicines. However, the market is probably hindered in the coming years by elevated competition from current market players, strict product approval laws by the government, and the absence of knowledge amongst rural populations in developing countries.

North America, followed by Europe, dominates the customized medicine industry in terms of income. The industry is evolving in Asia Pacific and Latin America. It is anticipated that this trend will proceed during the prediction. The market in those areas are expected to propel the availability of a big patient pool, expansion of the healthcare industry and increase public investments in improving healthcare. Due to increased knowledge among individuals of the use of customized medicine to treat multiple cancer kinds, and quick new products in customized medicine for different other illnesses, the customized medical market in nations such as Brazil, China and India is expected to grow at significantly increasing rates during a forecast period.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/personalized-medicine-market

Key Players & Strategies

Key companies in this market are Illumina, Inc.; Danaher Corporation Asuragen, Inc.; Abbott Laboratories; GE Healthcare; Dako A/S; Exagen Diagnostics, Inc.; Exact Science Corporation;Decode Genetics, Inc.; QIAGEN; Celera Diagnostics LLC; Genelex Corporation; Precision Biologics, Inc.; and Biogen, Inc.

These businesses invest in product-oriented technologies and company expansion developments. In April 2018, for example, Illumina provided economic assistance to multiple startup companies. TruGenomix Health, Inc., one of the starting companies, concentrated on individual therapy choices and promoted personalized treatments.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Personalized Medicine
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Personalized Medicine Market By Product
1.2.2.1. Global Personalized Medicine Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.2.2. Global Personalized Medicine Market Revenue Share By Product in 2017
1.2.2.3. Therapeutics
1.2.2.4. Diagnostics
1.2.2.5. Personalized Nutrition & Wellness
1.2.2.6. Personalized Medical Care
1.2.3. Personalized Medicine Market by Geography
1.2.3.1. Global Personalized Medicine Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.3.2. North America Personalized Medicine Market Revenue and Growth Rate (2015-2026)
1.2.3.3. Europe Personalized Medicine Market Revenue and Growth Rate (2015-2026)
1.2.3.4. Asia-Pacific Personalized Medicine Market Revenue and Growth Rate (2015-2026)
1.2.3.5. Latin America Personalized Medicine Market Revenue and Growth Rate (2015-2026)
1.2.3.6. Middle East and Africa (MEA) Personalized Medicine Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Personalized Medicine Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Personalized Medicine Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Personalized Medicine Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Personalized Medicine Major Manufacturers in 2017

CHAPTER 4. PERSONALIZED MEDICINE MARKET BY PRODUCT

4.1. Global Personalized Medicine Revenue By Product
4.2. Therapeutics
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Diagnostics
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.4. Personalized Nutrition & Wellness
4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.5. Personalized Medical Care
4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)

CHAPTER 5. NORTH AMERICA PERSONALIZED MEDICINE MARKET BY COUNTRY

5.1. North America Personalized Medicine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2. North America Personalized Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
5.3. U.S.
5.3.1. U.S. Personalized Medicine Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
5.4. Canada
5.4.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
5.5. Mexico
5.5.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)

CHAPTER 6. EUROPE PERSONALIZED MEDICINE MARKET BY COUNTRY

6.1. Europe Personalized Medicine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2. Europe Personalized Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
6.3. UK
6.3.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
6.4. Germany
6.4.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
6.5. France
6.5.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
6.6. Spain
6.6.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
6.7. Rest of Europe
6.7.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)

CHAPTER 7. ASIA-PACIFIC PERSONALIZED MEDICINE MARKET BY COUNTRY

7.1. Asia-Pacific Personalized Medicine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. Asia-Pacific Personalized Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. China
7.3.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.4. Japan
7.4.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.5. India
7.5.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.6. Australia
7.6.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.7. South Korea
7.7.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.8. Rest of Asia-Pacific
7.8.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)

CHAPTER 8. LATIN AMERICA PERSONALIZED MEDICINE MARKET BY COUNTRY

8.1. Latin America Personalized Medicine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Latin America Personalized Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. Brazil
8.3.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.4. Argentina
8.4.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.5. Rest of Latin America
8.5.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)

CHAPTER 9. MIDDLE EAST PERSONALIZED MEDICINE MARKET BY COUNTRY

9.1. Middle East Personalized Medicine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Middle East Personalized Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. Saudi Arabia
9.3.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.4. UAE
9.4.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.5. Rest of Middle East
9.5.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)

CHAPTER 10. AFRICA PERSONALIZED MEDICINE MARKET BY COUNTRY

10.1. Africa Personalized Medicine Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Africa Personalized Medicine Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. South Africa
10.3.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.4. Egypt
10.4.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.5. Rest of Africa
10.5.1. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)

CHAPTER 11. COMPANY PROFILE

11.1. Illumina, Inc.
11.1.1. Company Snapshot
11.1.2. Overview
11.1.3. Financial Overview
11.1.4. Product Portfolio
11.1.5. Key Developments
11.1.6. Strategies
11.2. Danaher Corporation
11.2.1. Company Snapshot
11.2.2. Overview
11.2.3. Financial Overview
11.2.4. Product Portfolio
11.2.5. Key Developments
11.2.6. Strategies
11.3. Asuragen, Inc.
11.3.1. Company Snapshot
11.3.2. Overview
11.3.3. Financial Overview
11.3.4. Product Portfolio
11.3.5. Key Developments
11.3.6. Strategies
11.4. Abbott Laboratories
11.4.1. Company Snapshot
11.4.2. Overview
11.4.3. Financial Overview
11.4.4. Product Portfolio
11.4.5. Key Developments
11.4.6. Strategies
11.5. GE Healthcare
11.5.1. Company Snapshot
11.5.2. Overview
11.5.3. Financial Overview
11.5.4. Product Portfolio
11.5.5. Key Developments
11.5.6. Strategies
11.6. Dako A/S
11.6.1. Company Snapshot
11.6.2. Overview
11.6.3. Financial Overview
11.6.4. Product Portfolio
11.6.5. Key Developments
11.6.6. Strategies
11.7. Exagen Diagnostics, Inc.
11.7.1. Company Snapshot
11.7.2. Overview
11.7.3. Financial Overview
11.7.4. Product Portfolio
11.7.5. Key Developments
11.7.6. Strategies
11.8. Exact Science Corporation
11.8.1. Company Snapshot
11.8.2. Overview
11.8.3. Financial Overview
11.8.4. Product Portfolio
11.8.5. Key Developments
11.8.6. Strategies
11.9. Decode Genetics, Inc.
11.9.1. Company Snapshot
11.9.2. Overview
11.9.3. Financial Overview
11.9.4. Product Portfolio
11.9.5. Key Developments
11.9.6. Strategies
11.10. QIAGEN
11.10.1. Company Snapshot
11.10.2. Overview
11.10.3. Financial Overview
11.10.4. Product Portfolio
11.10.5. Key Developments
11.10.6. Strategies
11.11. Celera Diagnostics LLC
11.11.1. Company Snapshot
11.11.2. Overview
11.11.3. Financial Overview
11.11.4. Product Portfolio
11.11.5. Key Developments
11.11.6. Strategies
11.12. Genelex Corporation
11.12.1. Company Snapshot
11.12.2. Overview
11.12.3. Financial Overview
11.12.4. Product Portfolio
11.12.5. Key Developments
11.12.6. Strategies
11.13. Precision Biologics, Inc.
11.13.1. Company Snapshot
11.13.2. Overview
11.13.3. Financial Overview
11.13.4. Product Portfolio
11.13.5. Key Developments
11.13.6. Strategies
11.14. Biogen, Inc.
11.14.1. Company Snapshot
11.14.2. Overview
11.14.3. Financial Overview
11.14.4. Product Portfolio
11.14.5. Key Developments
11.14.6. Strategies
11.15. Others
11.15.1. Company Snapshot
11.15.2. Overview
11.15.3. Financial Overview
11.15.4. Product Portfolio
11.15.5. Key Developments
11.15.6. Strategies

CHAPTER 12. RESEARCH APPROACH

12.1. Research Methodology
12.1.1. Initial Data Search
12.1.2. Secondary Research
12.1.3. Primary Research
12.2. Assumptions and Scope

Buy this Premium Research Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1466

The report is readily available and can be dispatched immediately after payment confirmation.

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.